Title page

The pharmacology and function of receptors for short chain fatty acids

Daniele Bolognini, Andrew B. Tobin, Graeme Milligan, and Catherine E. Moss

Molecular Pharmacology Group, Institute of Molecular, Cell and Systems Biology, University of Glasgow, Glasgow G12 8QQ, Scotland, United Kingdom (DB, GM) and Medical Research Council Toxicology Unit, University of Leicester, Leicester LE1 9HN, United Kingdom (CEM, ABT).

Running title page

Running title: Pharmacology of Short Chain Fatty Acid Receptors

Address correspondence to: Daniele Bolognini, Molecular Pharmacology Group, Wolfson Link Building 253, University of Glasgow, University Avenue, Glasgow G12 8QQ, UK or Catherine E. Moss, Medical Research Council Toxicology Unit, University of Leicester, Leicester LE1 9HN

Email: **cm619@leicester.ac.uk or daniele.bolognini@glasgow.ac.uk**

Text pages: 55

Number of figures: 3

Number of references: 114

Number of words in Abstract: 207

Number of words in text: 7367

ABBREVIATIONS

BHB, β-hydroxybutyrate; ECL, extracellular loop, fMLP, N-formylmethionyl-leucyl-phenylalanine; GPCR, G protein-coupled receptor; GSIS, glucose-stimulated insulin secretion; HDAC, histone deacetylase; HTS, high throughput screen, LE, ligand efficiency; NAM, negative allosteric modular; PAM, positive allosteric modulator; PBMC, peripheral blood mononuclear cell; PMN, polymorphic nucleocyte; PTX, pertussis toxin; ROS, reactive oxygen species; SAR, structure activity relationship, SCA,

small, non-fatty acid, carboxylic acids; SCFA, short chain fatty acids; TM

transmembrane; TPN, total parenteral nutrition

Chemical Names

4-CMTB, [(S)-2-(4-chlorophenyl)-3- methyl-N-(thiazol-2-yl)butanamide]; CATPB, (S)-

3-(2-(3-chlorophenyl)acetamido)-4-(4-(trifluoromethyl)phenyl)butanoic acid; compound

1, 3-benzyl-4-(cyclopropyl-(4-(2,5-dichlorophenyl)thiazol-2-yl)amino)-4-oxobutanoic

acid; GLPG0974, -[[(R)-1-(benzo[b]thiophene-3-carbonyl)-2-methyl-azetidine-2-

carbonyl]-(3-chloro-benzyl)-amino]-butyric acid; AR420626, N-(2,5-dichlorophenyl)-4-

(furan-2-yl)-2-methyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxamide; compound

6, 2-methyl-5-oxo-4-(3-phenoxyphenyl)-N-(o-tolyl)-1,4,5,6,7,8-hexahydroquinoline-3-

carboxamide; sorbic acid, 2,4-hexadienoic acid.

ABSTRACT

Despite some block-buster G protein-coupled receptor (GPCR) drugs only a small fraction (~15%) of the more than 390 non-odorant GPCRs have been successfully targeted by the pharmaceutical industry. One way that this issue might be addressed is via translation of recent de-orphanization programmes that have opened the prospect of extending the reach of new medicine design to novel receptor types with potential therapeutic value. Prominent among these receptors are those that respond to short chain free fatty acids of carbon chain length 2-6. These receptors, FFA2 (GPR43) and FFA3 (GPR41), are each predominantly activated by the short chain fatty acids acetate, propionate and butyrate, ligands that originate largely as fermentation by-products of anaerobic bacteria in the gut. However, the presence of FFA2 and FFA3 on pancreatic β-cells, FFA3 on neurons and FFA2 on leukocytes and adipocytes means that the biological role of these receptors likely extends beyond that of the widely accepted role of regulating peptide hormone release from enteroendocrine cells in the gut. Here we review the physiological roles of FFA2 and FFA3, the recent development and use of receptor selective pharmacological tool compounds and genetic models available to study these receptors, and present evidence of the potential therapeutic value of targeting this emerging receptor pair.

INTRODUCTION

Short Chain Fatty Acids (SCFAs) are saturated aliphatic organic acids containing 2 to 6 carbon atoms. Within the body they are predominantly the by-product of the fermentation of non-digestible carbohydrates (fibers) through the action of intestinal anaerobic bacteria (den Besten *et al.*, 2013). The amount of SCFAs released in the intestine is influenced by several factors, among which are the strain and quantity of microbiota in the colon, substrate source and intestinal transit time (Wong *et al.*, 2006). In general, SCFAs reach an intestinal concentration in the millimolar region, in which acetate (C2), propionate (C3) and butyrate (C4) represent the most abundant metabolite species (≥95%) (Topping and Clifton, 2001). In 2003, the previously orphan seven transmembrane (TM) domain polypeptides GPR41 and GPR43 were identified as G protein-coupled receptors (GPCRs) that are activated by SCFAs (Brown *et al.*, 2003; Le Poul *et al.*, 2003; Nilsson *et al.*, 2003). Following this discovery, interest surrounding SCFAs and their receptors has risen dramatically, both in relation to the discovery of selective ligands and the physiological role of these receptors. GPR41 and GPR43 were subsequently renamed FFA3 and FFA2, respectively (Stoddart *et al.*, 2008a) based on their responsiveness to SCFAs.

FFA2/FFA3 receptor structure and signal transduction

The genes encoding FFA2 and FFA3, together with the medium/long chain fatty acid receptor GPR40 (FFA1, Stoddart *et al.*, 2008a), cluster as a group of intronless sequences located in human at chromosome 19q13.1. They were first identified during a search for novel human galanin receptor subtypes (Sawzdargo *et al.*, 1997). A further gene that shares 98% identity with FFA3, was also identified within this region, and is designated

GPR42. This latter potential receptor is now classified as a functional polymorph of

FFA3, although its physiological role and expression in humans is yet to be fully clarified

(Liaw and Connolly, 2009; Puhl *et al.*, 2015). FFA2 and FFA3 are closely related, with

43% amino acid identity (Stoddart *et al.*, 2008a). This translates into poor ligand

selectivity between the two receptors. Nonetheless, there is a rank order of potency for

SCFAs in activating human FFA2 and FFA3 receptors, where FFA2 is activated more

potently by shorter chain fatty acids whilst, in general, the opposite is the case for FFA3.

Specifically, the rank order of potency for human FFA2 is reported as

C2=C3>C4>C5=C1, whereas at human FFA3 it is C3=C4=C5>C2>C1 (Milligan *et al.*,

2009) (**Figure 1**). Although this results in acetate being significantly more potent at

human FFA2 than at human FFA3 (Schmidt *et al.*, 2011) and is sometimes, therefore,

employed as a selective activator of FFA2, there is great need to identify more selective

synthetic ligands that would allow improved discrimination between the biological

functions of FFA2 versus FFA3 both *in vitro* and *in vivo*.

The de-orphanization of GPR41 and GPR43 led to the observation that the

carboxylic acid group of SCFAs is the key element in the activity of these endogenous

molecules at both receptors. Previous studies had shown that positively charged amino

acids within the TM regions are essential for the binding and function of other GPCRs

whose ligands contain a carboxylic acid group (Stitham *et al.*, 2003; He *et al.*, 2004;

Tunaru *et al.*, 2005; Sabirsh *et al.*, 2006). This, together with the observation that

uncharged ester derivatives of SCFAs are inactive at FFA2 and FFA3 (Le Poul *et al.*,

2003), led Milligan's group to hypothesize that basic residues might also play a crucial

role in the binding of SCFAs to their receptors (Stoddart *et al.*, 2008b). Sequence

alignment of FFA2 and FFA3 with FFA1 revealed that five positively charged amino

acids were conserved across these fatty acid receptors. Generation of homology models,

linked to a mutagenic strategy, was then employed to identify the key polar amino acids

for ligand recognition contained in the water-filled cavity within the TM domains of

FFA2 and FFA3 (Stoddart *et al.*, 2008b). From this, four positively charged amino acid

residues were identified: Histidine (His) in TM IV (residue position 4.56); Arginine (Arg)

in TM V (5.39); His in TM VI (6.55); Arg in TM VII (7.35) (Stoddart *et al.*, 2008b) (for a

more detailed consideration of the position and significance of these amino acids in FFA2

and FFA3 see Ulven, 2012). Studies in cells expressing alanine-substituted forms of these

residues in FFA2 and FFA3 led to the conclusion that both Arg 5.39 and 7.35, as well as

His 6.55, were essential for co-ordinating the recognition and functionality of SCFAs at

both FFA2 and FFA3. Indeed, in each case, these alterations completely abrogated

response to SCFAs (Stoddart *et al.*, 2008b). By contrast, mutation of His 4.56 displayed a

more diverse outcome between the two receptors, suggesting that this amino acid may not

be directly involved in the binding of the carboxylate group but, rather, plays a role in

fatty acid chain length selectivity (Stoddart *et al.*, 2008b). The identification of these key

residues involved in the orthosteric binding site paved the way for the study of other, and

potentially selective, small molecule ligands. Schimdt and colleagues established

structure-activity relationships (SAR) of a group of small, non-fatty acid, carboxylic

acids (SCAs) at FFA2 (Schimdt *et al.*, 2011). Although this work identified some

molecules that were relatively selective for FFA2 over FFA3, for example 2,2-

dimethylacrylic acid has approximately 800 times higher potency at FFA2 compared to

FFA3, the potency of such molecules was still very modest and too low to be useful as

pharmacological tools for *in vitro* and, particularly, *in vivo* studies. Given the small size

of these molecules, the low potency of both SCFAs and SCAs is hardly surprising.

However, they did display high ligand efficiency (LE). LE is a measure of ligand binding

free energy per heavy atom count and is mathematically expressed by delta g (Hopkins *et*

al., 2014). This concept has been widely used for the selection and optimization of

fragments or small ligands at specific pharmacological targets. Schmidt *et al.* (2011)

indicated that the ligand efficiency for C2, C3 and SCAs was approaching the maximal

possible delta g value, indicating that it would be unlikely that potency at FFA2 and

FFA3 could be improved without increasing ligand size substantially.

An additional binding pocket in FFA2, distinct from that for the endogenously

produced SCFAs, was first hypothesized by researchers at Amgen. This was based on

outcomes from a high throughput screen (HTS) campaign to identify FFA2 activators

(Lee *et al.*, 2008). This resulted in the characterization of the first moderately potent

FFA2 selective, synthetic ligand, [(S)-2-(4-chlorophenyl)-3- methyl-N-(thiazol-2-

yl)butanamide] (4-CMTB) (**Figure 1**). This ligand was shown to cause activation of both

$G\alpha_{i/o}$ and $G\alpha_{q/11}$-mediated pathways via FFA2 with no effect at FFA3 (Lee *et al.*, 2008).

Despite this, some subsequent studies have indicated very limited ability of this ligand to

produce elevation of Ca^{2+} levels in transfected cells (see later). Moreover, further

analyses of the pharmacological properties of this ligand revealed an ability to exert

positive cooperativity with both C3 and C2, indicating that 4-CMTB behaves as an

allosteric agonist at FFA2 (Lee *et al.*, 2008; Wang *et al.*, 2010; Smith *et al.*, 2011).

Mutagenic studies have revealed that extracellular loop 2 (ECL2) plays an important role

in the allosteric effect of 4-CMTB. Replacement of ECL2 in FFA2 with the equivalent

region from FFA3 completely abolished the observed positive cooperativity between 4-CMTB and C3 (Smith *et al.*, 2011). Despite this, the details of the 'allosteric' binding pocket for 4-CMTB remain to be fully defined.

As noted earlier, in terms of signal transduction FFA2 is a promiscuous receptor that has the ability to couple to pathways transduced by both $G\alpha_{i/o}$ and $G\alpha_{q/11}$ proteins (Brown *et al.*, 2003; Le Poul *et al.*, 2003; Nilsson *et al.*, 2003). Moreover, screens performed in strains of the yeast *S. cerevisiae* containing different yeast/mammalian $G\alpha$ subunit chimeras, also indicated an ability of FFA2 to interact with $G\alpha_{12}$, $G\alpha_{13}$ and $G\alpha_{14}$ (Brown *et al.*, 2003). However, interaction of FFA2 with these G proteins has yet to be validated in cells that express native, full length mammalian G proteins. By contrast, the activation of FFA3 appears to induce only $G\alpha_{i/o}$-mediated signaling as receptor effects are generally attenuated by pertussis toxin (PTX) treatment of cells (Brown *et al.*, 2003; Le Poul *et al.*, 2003). In addition, SCFA occupancy of FFA2 has been reported to recruit both β-arrestin-1 and, in particular, β-arrestin-2 to the receptor and these are responsible for FFA2 internalization from the cell surface and the initiation of G protein-independent signal transduction (Hudson *et al.*, 2012b and 2013b; Lee *et al.*, 2013). To date there are no published data regarding the ability of FFA3 to recruit arrestin isoforms.

Physiological roles of FFA2/FFA3

Roles in immune cells

When the tissue expression of FFA2 was first described, its most notable presence was in cells of the innate immune system, both polymorphic nucleocytes (PMNs) and peripheral blood mononuclear cells (PBMCs) (Le Poul *et al.*, 2003) (**Figure 2**). Recent

studies have confirmed presence of FFA2 in neutrophils, eosinophils (Maslowski *et al.*, 2009), and in leukocytes of the lamina propia (Nøhr *et al.*, 2013). The presence of FFA3 remains contentious (Brown *et al.*, 2003; Maslowski *et al.*, 2009). Naturally, given that SCFAs are a by-product of anaerobic fermentation by gut bacteria, it is to be expected that immune cells should be able to respond to such ligands.

One area of particular interest is inflammatory conditions of the lower gut, such as ulcerative colitis and Crohn's disease (Xavier and Podolsky, 2007). Butyrate enemas have been used to attempt to treat colitis, with mixed results (Bocker *et al.*, 2003), and a high fiber diet can result in improvement in ulcer and colitis scores, with matching reduction in neutrophil infiltration (Kataoka *et al.*, 2008). Despite these promising results, two different studies examining the role of FFA2 in rodent models of colitis have generated conflicting effects. Maslowski *et al.* (2009) found that colitis could be rescued in germ-free mice by FFA2 agonism with acetate, whereas Sina *et al.* (2009) found that SCFA recruit PMNs via FFA2 to worsen tissue damage. Moreover, a`first in man` clinical trial with the FFA2 antagonist, GLPG0974 (see later), for the treatment of ulcerative colitis did not provide any immediate beneficial effects, resulting in this study being terminated. Clearly, FFA2 signaling in leukocytes is a complicated scenario, which deserves further dissection and analysis.

Most reports suggest that SCFAs mediate a shift from pro-inflammatory to anti-inflammatory cytokine release from leukocytes. C2 and C4 can inhibit TNF-α release (Säemann *et al.*, 2000; Maslowski *et al.*, 2009; Ohira *et al.*, 2013), and C4 in particular can mediate a switch from a Th1 (which is exaggerated in Crohn's disease) to a Th2 profile of cytokine production (Säemann *et al.*, 2000; Cavaglieri *et al.*, 2003). Both FFA2

and FFA3 knock-out mice do not recruit Th1 cells in a rectal inflammation model (Kim

et al., 2013). Finally, C3 can trigger the release of the anti-inflammatory IL-10 from

regulatory T cells, and this happens in a FFA2-specific manner (Smith *et al.*, 2013).

In terms of cell signaling, C2 and C3 (Le Poul *et al.*, 2003; Maslowski *et al.*,

2009) but not C4 (Nakao *et al.*, 1992) increase intracellular Ca^{2+} in PMNs, in a manner

that has been described as partially (Nakao *et al.*, 1992) or fully PTX insensitive, and

intracellular store-dependent (Le Poul *et al.*, 2003), raising the possibility that this effect

may be mediated via FFA2 and $G\alpha_{q/11}$. PMNs require calcium for chemotaxis towards N-

formylmethionyl-leucyl-phenylalanine (fMLP), a peptide which is often used as a model

of bacteria-stimulated chemotaxis (Chen and Jan, 2001). PMNs migrate along a C3 or C4

gradient, in a FFA2, p38, ERK1/2, and pAkt specific manner; and this appears to be

PTX-sensitive, implicating $G\alpha_{i/o,}$ in addition to $G\alpha_{q/11}$ (Sina *et al.*, 2009; Vinolo *et al.*,

2011). Neutrophils use reactive oxygen species (ROS) in phagosomes to kill internalized

bacteria (Nordenfelt and Tapper, 2011), but ROS also play a role as signaling molecules

involved in chemotaxis (Hattori *et al.*, 2010). C4 inhibits ROS production in neutrophils

stimulated with fMLP via cAMP, and a PTX-sensitive release of G protein $G_{\beta\gamma}$ complex.

Conversely, C2 increases ROS production in a PTX-insensitive manner (Vinolo *et al.*,

2009), and macrophages lacking FFA2 do not produce ROS in a model of gouty arthritis

(Vieira *et al.*, 2015). Potentially this may reflect opposing signaling via FFA2 and $G\alpha_{q/11}$

and FFA3 and $G\alpha_{i/o}$. ROS also contribute to apoptosis in neutrophils - a process which

helps limit the extent of inflammation (Nordenfelt and Tapper, 2011) – and C2 increases

apoptosis (Maslowski *et al.*, 2009), perhaps again via FFA2.

Broadly speaking, it would appear that C2 and C3 stimulate, whilst C4 inhibits, the various functions of innate immune cells. This may explain conflicting results using mixes of SCFAs, although non-receptor mediated effects cannot be ruled out. In terms of cytokine release, all SCFAs appear to have anti-inflammatory effects. There are not yet many data demonstrating the signaling pathways upstream of cytokine release, or indeed whether both FFA2 and FFA3 are involved. As with analysis of function of FFA2 and FFA3 in other tissues (see later), the low potency and pleiotropic effects of the SCFAs, means that without access to new, well characterized and highly selective synthetic ligands, unravelling the specific roles of FFA2 and FFA3 in immune cells and in immune cell-mediated disease processes will remain challenging.

Roles in the intestine

C4 is an important energy source for enterocytes, and SCFAs have a multitude of positive effects in the colon, such as helping maintain the intestinal barrier, and decreasing the risk of cancer (Canani *et al.*, 2011) (**Figure 2**). Indeed, model animals on total parenteral nutrition fare better when supplemented with SCFAs, showing less mucosal atrophy, an improvement that correlates with increased expression of proglucagon (Gee *et al.*, 1996; Pratt *et al.*, 1996; Tappenden and McBurney, 1998). Studies using fluorescently labelled L-cells show FFA2 to be highly expressed in colonic L-cells, and FFA3 in small intestinal L-cells (Tolhurst *et al.*, 2012). FFA3 partially co-localizes with gastrin and ghrelin in the stomach, completely co-localizes with CCK, GIP and secretin in the proximal small intestine and with PYY, NT, and GLP-1 in the distal small intestine. A gradient of expression of FFA3 increases distally in D-cells and

enterochromaffin cells. Conversely, FFA2 is only observed sparsely in a subpopulation of enteroendocrine cells of the small intestine, although the lack of fluorescence in the model used cannot be taken to be conclusive proof of lack of expression (Nøhr *et al.*, 2013). In accordance with the expression profile of FFA2 and FFA3, stimulation of enteroendocrine cells with SCFAs can trigger GLP-1 (Reimer and McBurney, 1996; Lin *et al.*, 2012; Tolhurst *et al.*, 2012; Nøhr *et al.*, 2013; Psichas *et al.*, 2015), GLP-2 (Akiba *et al.*, 2015) PYY (Lin *et al.*, 2012; Psichas *et al.*, 2015) and GIP (Lin *et al.*, 2012) release. However, reports as to whether oral SCFA can increase enteroendocrine hormones *in vivo* are mixed. One study found oral SCFAs had no effect on GLP-1, but decreased the plasma GIP response to glucose challenge (Tang *et al.*, 2015). FFA2 agonists may also act on EC cells to trigger 5-HT release, which together with GLP-2 would help prevent mucosal injury (Akiba *et al.*, 2015), suggesting a mechanism for the benefits to adding SCFAs to TPN. Finally, there is a link between SCFAs and decreased intestinal motility, which is FFA3 and neuroendocrine independent (Dass *et al.*, 2007). Overall, results show that FFA2 and FFA3 are involved in enteroendocrine hormone production and intestinal functions, but further studies with selective synthetic ligands and new animal models are needed to better define the roles of these receptors in the intestine.

Roles in the pancreas

Early reports showed that C2 improves glucose clearance in rats (Shah *et al.*, 1977), and improves glucose-stimulated insulin secretion (GSIS) in isolated rat islets (Patel and Singh, 1979). More recently it has been demonstrated that islets express both

FFA2 and FFA3 (Brown *et al.*, 2003; Leonard *et al.*, 2006; Regard *et al.*, 2007) (**Figure 2**), and crucially they are found in beta cells of the islet (Tang *et al.*, 2011). Interestingly, FFA2 is upregulated in pregnancy in the mouse, suggesting that it may aid in this insulin-resistant state (Layden *et al.*, 2010). This suggests a simple relationship of FFA2/3 agonism leading to insulin secretion, but the reality is likely to be more complicated. One study has reported that while C2 increases insulin secretion via FFA2 (Priyadarshini *et al.*, 2015), C3 inhibits insulin secretion via FFA3 (Priyadarshini and Layden, 2015). Other results indicate that C2 has an autocrine role, suggesting it to inhibit insulin secretion via $G\alpha_{i/o}$ coupled to both FFA2 and FFA3 in beta cells (Tang *et al.*, 2015). The latter appears more logical, given the importance of cAMP in boosting GSIS (Yajima *et al.*, 1999). Interpretation must remain cautious at this point, however, because it is possible that different SCFAs display ligand bias (see later) at FFA2/3. For example, FFA2 agonist-mediated enhancement of GSIS activation is reported to be via PLCβ (Priyadarshini *et al.*, 2015). Perhaps FFA2-dependant effects of C2 in the islet are biased to $G\alpha_q$ over $G\alpha_{i/o}$. Studies in FFA2 knock-out mice showed a depressed level of plasma insulin in response to an oral glucose load, but it is difficult to draw firm conclusions from these data given that FFA2 also plays a role in GLP-1 secretion (Tolhurst *et al.*, 2012) and insulin sensitivity (Bjursell *et al.*, 2011), both of which would be anticipated to have a knock-on effect on insulin levels. To describe separate, potentially opposing roles of FFA2 and FFA3 in the islet, selective ligands for each receptor are sorely needed.

Roles in adipose tissue

There is strong evidence for the presence of FFA2 in adipocytes (**Figure 2**). Two of the original de-orphanization studies noted this (Brown *et al.*, 2003; Le Poul *et al.*, 2003), and subsequent studies have agreed (Ge *et al.*, 2008; Al-Lahham *et al.*, 2010; Lemor *et al.*, 2010; Kimura *et al.*, 2013). The presence of FFA3, however, remains a subject of debate. FFAR3 mRNA is reported to be in adipose tissue and adipocyte cell lines (Le Poul *et al.*, 2003; Xiong *et al.*, 2004; Mielenz *et al.*, 2008; Al-Lahham *et al.*, 2010) but, equally, many groups report that adipocytes themselves do not possess the receptor (Brown *et al.*, 2003; Hong *et al.*, 2005; Zaibi *et al.*, 2010; Bellahcene *et al.*, 2013). Knocking out FFA2 expression has not provided clarity as to its possible function in adipocytes. FFA2 receptor knock-out lines have been reported to show both increase adiposity (Kimura *et al.*, 2013), and protect against diet-induced obesity (Bjursell *et al.*, 2011). In addition, lean and obese humans have similar expression levels of FFA2 (Dewulf *et al.*, 2013). Still, it is clear that SCFAs act on adipocytes. C2 derived from alcohol metabolism reduces circulating FFAs (Crouse *et al.*, 1968), and resistant starch supplementation inhibits lipolysis and hormone-sensitive lipase to the same effect (Robertson *et al.*, 2005; Ge *et al.*, 2008). Exogenous C2, C3 and C4 all inhibit lipolysis (Hong *et al.*, 2005; Ge *et al.*, 2008; Zaibi *et al.*, 2010). Importantly this effect is PTX-sensitive (Ohira *et al.*, 2013), and absent in FFA2 knock-out mice (Ge *et al.*, 2008). Reports suggest that FFA2 activation reduces insulin sensitivity in the adipocyte, by $G_{\beta\gamma}$-mediated inhibition of Akt phosphorylation downstream of the insulin receptor (Kimura *et al.*, 2013).

SCFA can drive adipocyte differentiation from stem cells (adipogenesis). C2 and C3 trigger the pre-adipocyte cell line 3T3-L1 to differentiate, and C3 increases

expression of the adipogenesis markers PPAR-γ2 and C/EBPα. When these cells are treated with siRNA against FFA2, expression of PPAR-γ2 and aP2 (another adipocyte marker) decrease (Hong *et al.*, 2005). FFA2 knock-out mice have less adipocytes (Bjursell *et al.*, 2011) but, curiously, these findings from rodent models may not translate to humans. Adipocytes cultured from the omentum did not show any increase in aP2 after treatment with FFA2 agonists (Dewulf *et al.*, 2013). A lack of difference in white adipose tissue between FFA2 knock-out and wild type pups in the embryonic stage have even led one group to conclude that the effect of FFA2 in adipogenesis may be an *in vitro* artefact (Kimura *et al.*, 2013).

Finally, the adipocyte does not function as merely an inert energy store; it is also an endocrine cell, secreting metabolic hormones including adiponectin and leptin (Sethi and Vidal-Puig, 2007). Higher levels of leptin have been reported in both FFA2 (Bjursell *et al.*, 2011) and FFA3 knock-out mice fed a high fat diet (Bellahcene *et al.*, 2013) although a different FFA2 knock-out line had plasma leptin levels comparable to wild type (Kimura *et al.*, 2013). *In vitro*, SCFAs also increase leptin mRNA in bovine adipocytes (Soliman *et al.*, 2007) and increase leptin secretion from primary murine adipocytes (Xiong *et al.*, 2004), both in a PTX-sensitive manner. As all these somewhat contradictory studies demonstrate, the true role of the FFA2 in the adipocyte is far from fully defined.

Roles in neurons

The autonomic nervous system regulates energy output, and in particular the sympathetic nervous system acts to decrease energy use during periods of starvation

(Kimura *et al.*, 2011). It has been proposed that SCFAs can act at FFA3 as a switch to modulate sympathetic regulation of energy. In times of plenty, plasma levels of C4 will increase (especially if diets are high in fiber) (Nilsson *et al.*, 2010), whereas during starvation, levels of ketone bodies such as β-hydroxybutyrate (BHB) – a putative FFA3 antagonist (Inoue *et al.*, 2012) (or possibly agonist) (Won *et al.*, 2013) will increase.

FFA3 is expressed by both prevertebral and paravertebral ganglia (Kimura *et al.*, 2011; Won *et al.*, 2013; Nøhr *et al.*, 2015) (**Figure 2**). FFA3 knock-out mice have a lower resting heart rate, and less sympathetic innervation of the heart, whereas C3 given to wild type mice can raise heart rate. Co-culturing cardiomyocytes and neurons together reveals a FFA3-dependent relationship where C3 can increase beat rate. This effect is PTX-sensitive, and involves $G_{\beta\gamma}$, PLCβ, and ERK/12 MAP kinases. In this system, BHB can antagonize the effect of C3 (Kimura *et al.*, 2011). C3 causes the release of noradrenaline from the superior cervical ganglion via the same signaling cascade and synapsin 2. Again, this is inhibited by BHB (Inoue *et al.*, 2012). However, there is a conflicting report that describes a different mechanism of FFA3 action. Won *et al.*, (2013) showed inhibition of N-type Ca^{2+} channels by $G_{\beta\gamma}$ complex generated by activation of FFA3, an effect that was elicited by each of C2, C3 and BHB, and would presumably decrease catecholamine release from neurons (Won *et al.*, 2013). How these data fit within the sympathetic modulation theory remains to be defined.

FFA3 is also expressed in ganglia of the enteric and sensory nervous systems, i.e. submucosal ganglia, myenteric ganglia, nodose ganglion, dorsal root ganglia, and trigeminal ganglia (Nøhr *et al.*, 2013, 2015). The physiological function of FFA3 in these ganglia has yet to be described. Finally, FFA3 co-localizes with a neuronal marker in the

portal vein wall, where it is proposed that C3 can act to form a gut-brain axis regulating

intestinal gluconeogenesis (De Vadder *et al.*, 2014).

Experimental challenges and current perspectives for the validation of FFA2/FFA3 as

therapeutic target(s)

Target validation is an essential step in drug-development studies and assists in

defining the physiological role(s) of a GPCR and its importance in patho-physiological

conditions, with the aim of developing a pipeline of potential therapeutic medicines

(Smith, 2003). Among several approaches, validation of a GPCR can be achieved by

employing ligands that selectively perturb the target of interest *in vitro* and/or *in vivo*.

Synthetic ligands for SCFA receptors

There is a general paucity of selective ligands for FFA2 and FFA3 and the co-expression

of these two GPCRs in several tissues (see earlier) presents major obstacles in

understanding the patho-physiological role of each receptor. This is further complicated

by differences between the pharmacology of species orthologs of FFA2 and FFA3

(**Figure 1**). For example, although C2 has been used in a number of *in vivo* studies both

because it is the most abundant SCFA in the body (McOrist *et al.*, 2008) and because of

its reported selectivity for FFA2 over FFA3 (Schmidt *et al.*, 2011), this selectivity of C2

is most pronounced at the human SCFA receptors. By contrast, (Hudson *et al.*, 2012b)

demonstrated that this is not the case for the murine orthologs of FFA2 and FFA3

(**Figure 1**). Indeed, for the mouse receptors C2 is equipotent in activating FFA2 and

FFA3. Moreover, no endogenous SCFA is sufficiently selective to define a role for FFA2

over FFA3, or *vice versa*, in murine cells and tissues (Hudson *et al.*, 2012b). This highlights the need for more potent and markedly more selective ligands for the two receptors.

Orthosteric agonist ligands

Pleiotropic non-receptor-mediated effects, as well as the low potency and lack of selectivity of the SCFAs between FFA2 and FFA3, has certainly become a major obstacle to the study of the function of these receptors, both *in vitro* and *in vivo*. The work of Schmidt *et al.* (2011) highlighted that although small molecules containing a carboxylic acid group can achieve close to optimal LE and a reasonable degree of selectivity at FFA2 vs FFA3, their modest potency, and a lack of knowledge of potential 'off-target' effects, means they remain unsuitable for *ex-vivo* and/or *in vivo* study of these receptors, although they have been used in a limited number of cases (e.g. Priyadarshini *et al.*, 2015).

The first class of more potent synthetic ligands of FFA2 were initially described and patented by Euroscreen (Hoveyda *et al.*, 2010). From this series of ligands, Hudson *et al.*, (2013b) synthesized and characterized 'compound 1' (3-benzyl-4-(cyclopropyl-(4-(2,5-dichlorophenyl)thiazol-2-yl)amino)-4-oxobutanoic acid) as a selective orthosteric agonist at human FFA2 (**Figure 1**). In a range of assays, including those reflecting FFA2-mediated $G\alpha_{i/o}$, $G\alpha_{q/11}$ and β-arrestin pathways, this ligand is able to activate human FFA2 with potency in the high nanomolar range. The mode of binding of this ligand has not yet been completely elucidated. 'Compound 1' and related molecules contain a carboxylic acid pharmacophore, and this is required for function because replacement by

a methyl or *tert*-butyl ester eliminates activity (Hudson *et al.*, 2013b). Moreover, it is

clearly orthosteric in action as it also lacks function at mutants of the key positively

charged residues of the orthosteric binding site of human FFA2 (Hudson *et al.*, 2013b).

Moreover, function of 'compound 1' is inhibited by the orthosteric antagonist, CATPB

(Hudson *et al.*, 2013b) in a competitive and surmountable fashion. However, 'compound

1' contains also the N-thiazolyamide pharmacophore, as found in the allosteric agonist 4-

CMTB. Despite this, 'compound 1' does not appear to act as a 'bitopic' ligand (Lane *et

al.*, 2013) because in β-arrestin-2 recruitment assays 'compound 1' did not also display

competitive interactions with 4-CMTB (Hudson *et al.*, 2013b). Studies with related

compounds, designated 9, 14, 101 and 105, containing both carboxylate and N-

thiazolyamide moieties (Brown *et al.*, 2015) indicated these ligands were also able to

interact with the orthosteric binding site of FFA2, but not with the allosteric binding site.

In cells endogenously expressing FFA2 'compound 1' has been reported to reduce

lipolysis in both the human and mouse immortalized adipocyte cell lines, SW872 and

3T3-L1 respectively, with a mechanism that has been shown to be $G\alpha_{i/o}$ dependent.

Moreover, 'compound 1' has also been reported to induce GLP-1 release from the murine

STC-1 enteroendocrine cell line (Hudson *et al.*, 2013b). Importantly, although

'compound 1' displays reasonable potency at rodent orthologs of FFA2 (Hudson *et al.*,

2013b), certain other compounds from this chemical series show markedly lower potency

at the rodent forms compared to human (Hudson *et al.*, 2013b). Although potentially a

good deal might be learned from a systematic SAR analysis of this compound series,

such studies have not been reported to date. Docking studies of 'compound 1' to a

homology model of human FFA2 revealed that the phenyl substituent in this ligand may

interact with residue position 3.29 of the receptor (Hudson *et al.*, 2013b). Interestingly,

this residue differs between human (serine) and rodent (glycine) orthologs. More

recently, a further homology model of this receptor, based on the x-ray structure of the

related receptor FFA1, has indicated that tyrosine 90 (residue position 3.33) is also in

close proximity to this phenyl ring (Sergeev *et al.,* 2016) and mutation of this residue has

also previously been shown to markedly reduce the potency of 'compound 1' (Hudson *et al.*, 2013b).

Orthosteric antagonist ligands

Receptor antagonists, by blocking the action of either endogenous or synthetic

agonists, routinely provide powerful tools to help define biological roles of a receptor.

Interest in the biological actions and potential therapeutic application of FFA2

antagonists emerged with the discovery that FFA2 is expressed by neutrophils and can

dictate their migration in inflammatory states, including those of the lower intestine

(Maslowski *et al.*, 2009; Sina *et al.*, 2009). Moreover, recent studies have showed that

FFA2 and FFA3 activation in beta cells of the pancreas can block insulin secretion (Tang

et al., 2015), suggesting that antagonists at either (or both) of these receptors could be

beneficial for the treatment of type II diabetes.

In recent years, two series of FFA2 antagonists have been described. The first

series of antagonists was reported by Euroscreen (Brantis *et al.*, 2011). Among those

compounds, (S)-3-(2-(3-chlorophenyl)acetamido)-4-(4-(trifluoromethyl)phenyl)butanoic

acid (CATPB) (**Figure 1**) inhibited effects of C3 in cells expressing human FFA2 in both

$[^{35}S]$GTPγS binding and calcium-based assays, with reported pIC$_{50}$ of 7.70 and 8.00,

respectively (Brantis *et al.*, 2011). Lack of effect in cells expressing FFA3 indicated

CATPB to be specific for FFA2. Experiments using [^{3}H]CATPB showed that C3 was

able to fully displace the radiolabeled ligand, consistent with, although not defining, that

CATPB binds to the orthosteric site of human FFA2 (Brantis *et al.*, 2011). Subsequent

experiments employing [^{35}S]GTPγS binding revealed that CATPB was also able to

decrease the constitutive activity of human FFA2 expressed in HEK293 cells, indicating

that CATPB acts as an inverse agonist at this receptor (Hudson *et al.*, 2012b).

The second series of FFA2 receptor antagonists contains an azetidine

pharmacophore and was reported by Galapagos NV as potentially of interest for their

effects in metabolic and inflammatory disorders, based on an ability to block SCFA-

induced neutrophil migration (Sanière *et al.*, 2012). The most studied compound from

this series is 4-[[(R)-1-(benzo[b]thiophene-3-carbonyl)-2-methyl-azetidine-2-carbonyl]-

(3-chloro-benzyl)-amino]-butyric acid (GLPG0974) (**Figure 1**). This ligand showed high

potency to antagonize acetate-mediated Ca^{2+}-elevation, with a reported pIC_{50} of 8.04

(Pizzonero *et al.*, 2014). Using human neutrophils this compound blocked both acetate-

induced migration and expression of the neutrophil activation marker, CD11b[AE],

consistent with a potential capacity of GLPG0974 to decrease inflammatory processes

(Pizzonero *et al.*, 2014). Good pharmacodynamic properties and the pharmacokinetic

profile of this ligand resulted in 'first in man' trials of GLPG0974 in a phase 2,

randomized, double blind, and placebo-controlled clinical trial in 2013. During this study,

the safety and efficacy of the compound were tested in patients affected by mild to

moderate ulcerative colitis. However, no improvement in the clinical profile of patients

over a short-term treatment resulted in termination of this programme.

FFA2 antagonists could represent an extremely useful tool for pre-clinical drug development and proof of concept studies. Unfortunately neither of the FFA2 antagonists that have been described to date in primary peer-reviewed publications (CATPB and GLPG0974) appear able to interact with rodent orthologs of FFA2 (**Figure 1**). Recently, Sergeev and colleagues analyzed the binding interaction of [^{3}H]GLPG0974 at hFFA2. From this study it emerged that the orthosteric antagonists, GLPG0974 and CATPB, do not require interaction with both Arginine residues, Arg 5.39 and 7.35, in the orthosteric binding pocket in order to engage with the receptor (Sergeev *et al.*, 2016). In addition, it was found that these different classes of antagonists displayed preferential interaction with different arginine residues (Sergeev *et al.*, 2016). The characterization of ligand-receptor interactions is likely to be important for the design of ligands that also display antagonism at rodent orthologs of the receptor.

Allosteric ligands

Allosteric modulators are defined as ligands that interact at a site of a receptor which is distinct from and does not overlap with the orthosteric binding site. The interaction of a ligand with an allosteric binding site can generate a conformational change in the receptor that is transduced to the orthosteric site and/or directly to the intracellular effector (Kenakin and Miller, 2010; Wooten *et al.*, 2013). Allosteric ligands can regulate the affinity and/or the potency of orthosteric ligands in a positive (positive allosteric modulators, PAMs) or negative (negative allosteric modulators, NAMs) manner (Kenakin and Miller, 2010; Wooten *et al.*, 2013). Molecules may also bind to the allosteric site but have no effect on receptor activity in which case they are called neutral

allosteric ligands (NALs). In addition to potentially modulating the activity of orthosteric ligands allosteric modulators may also possess agonist activity, or intrinsic activity, in their own right (Kenakin and Miller, 2010; Wootten *et al.*, 2013). This is often only evident at high levels of occupancy of the allosteric site and in highly sensitive signal transduction assays.

Therapeutically, allosteric ligands potentially offer certain advantages over orthosteric ligands. This includes improved selectivity due to the fact that allosteric sites are often in non-conserved regions of the receptor and that the co-operativity of allosteric ligands can be receptor subtype specific. Furthermore, the effects of allosteric modulators are saturable, and this can limit possible side-effects including overdose. Moreover, PAMs and NAMs have the advantage of maintaining both temporal and spatial properties of endogenous ligand function, without altering or disrupting the physiological system (Kenakin and Miller, 2010; Wootten *et al.*, 2013).

Currently phenylacetamides, of which 4-CMTB (**Figure 1**) is by far the most studied example, represent the only described class of allosteric modulators at FFA2. 4-CMTB is an allosteric agonist at FFA2 in that it has the ability to activate $G\alpha_{i/o}$, $G\alpha_{q/11}$ and β-arrestin-mediated FFA2 pathways directly as well as behaving as a PAM of the potency of SCFAs (Lee *et al.*, 2008; Wang *et al.*, 2010; Smith *et al.*, 2011). However, some studies suggest that 4-CMTB might affect various FFA2-mediated signaling responses somewhat differently than SCFAs (Smith *et al.*, 2011). Whether 4-CMTB displays 'functional selectivity' (Hudson *et al.*, 2013a) at FFA2 thus deserves further investigation.

In vitro, 4-CMTB has been found to produce inhibition of lipolysis in both mouse and human adipocytes (Lee *et al.*, 2008; Wang *et al.*, 2010; Brown *et al.*, 2015), to induce GLP-1 release from enteroendocrine cells (Brown *et al.*, 2015) and to promote chemotaxis of neutrophils (Vinolo *et al.*, 2011). Unfortunately, 4-CMTB has poor pharmacokinetic properties (Wang *et al.*, 2010) and consequently it is not suitable for *in vivo* validation of FFA2.

There is an even greater paucity of available FFA3-selective ligands. The only currently described class of synthetic ligands was identified by Arena Pharmaceuticals (Leonard *et al.*, 2006). This series of ligands was later shown to contain each of allosteric agonists, PAMs, NAMs and PAM-antagonists (Hudson *et al.*, 2014), although the basis for the SAR of such effects remains uncharted. One compound derived from this series, AR420626 (**Figure 1**), has been used to demonstrate the involvement of SCFAs in both GLP-1 secretion from colonic crypts (Nøhr *et al.*, 2013) and ghrelin secretion from gastric mucosa cells (Engelstoft *et al.*, 2013). Although this class of compounds needs to be further developed and characterized, the diverse and rather complex pharmacology of this series of ligands could provide new insight into the biological functions of FFA3. Interestingly, FFA2 and FFA3 allosteric modulators show similar function at human and rodent orthologs of those receptors, where they retain both their potency and allosteric properties (Lee *et al.,* 2008; Hudson *et al.,* 2012b and 2014). This is in contrast to the behavior of the synthetic orthosteric ligands discussed above. Although it has been reasoned that allosteric binding sites should be under less evolutionary pressure to be maintained than orthosteric sites because endogenously produced regulators do not bind to these regions (May *et al.*, 2007, Hudson *et al.*, 2013a), it has been helpful that the

allosteric ligands described above do display function at rodent orthologues of FFA2 and FFA3. Considering that different species ingest different amounts of fiber and they are consequently exposed to varying concentrations of SCFAs (Dranse *et al.*, 2013; Milligan *et al.*, 2014), it is reasonable to imagine that this may have driven alterations in the orthosteric binding site between species (Hudson *et al.*, 2014). This could be extremely important in terms of drug development programs. As already introduced, as well as showing activity at the human receptor, ligands preferably should show activity in different species as pre-clinical studies are performed in animal models. In this regard, allosteric modulators at FFA2 could be useful approach to validate FFA2/FFA3 *in vitro* and *in vivo*.

Biased ligands

In the last 20 years it has become clear that some ligands have the ability to preferentially activate specific receptor-mediated intracellular signaling pathways over others. This phenomenon is defined as "biased signaling" or "functional selectivity" and is believed to reflect the capacity of a receptor to adopt multiple activated states and/or the ability of a ligand to preferentially induce specific receptor active states (Kenakin, 2013; Kenakin and Christopoulos, 2013). It has been suggested that such 'biased' ligands may have clinical benefit if they can facilitate beneficial physiological processes without simultaneously driving signals that may be contra-indicated. This has generated many ideas in ligand design and, although still to be shown directly to result in clinical benefit, highlights the need to pharmacologically characterize ligands in an array of functional assays (Kenakin and Christopoulos, 2013; Kenakin, 2015). FFA2 in particular has been

reported to be a promiscuous receptor due to its ability to interact with various G proteins and also to recruit arrestins (Brown *et al.*, 2003; Stoddart *et al.*, 2008b). Signal bias is certainly not restricted to synthetic ligands. For example, endogenous ligands for chemokine receptors clearly exert bias (Zweemer *et al.*, 2014) and for receptors, such as FFA2, that respond to multiple endogenously generated ligands, there may be potential for these to display variation in signal flux.

At present it is unclear whether different SCFAs display bias or indeed, whether such bias at SCFA receptors could have a therapeutic application. Certainly, however, biased agonists at FFA2 or FFA3 would be invaluable tools to understand the physiological implications of distinct signaling pathways to the biological effect of these receptors. For example, the role of FFA2 in pancreatic beta cells remains controversial (Priyadarshini *et al.*, 2015; Tang *et al.*, 2015). Nonetheless, $G\alpha_{q/11}$ and $G\alpha_{i/o}$-dependent pathways in beta cells seem to exert opposite effects relative to insulin secretion, with activation of $G\alpha_{q/11}$ signaling leading to increased levels of this hormone, and of $G\alpha_{i/o}$ to diminished secretion (Winzell and Ahrén, 2007; Priyadarshini *et al.*, 2015). Whether FFA2 activation in human pancreatic islets can signal through both $G\alpha_{q/11}$ and $G\alpha_{i/o}$ pathways is still unclear. However, a biased agonist at FFA2 that would preferentially function through $G\alpha_{q/11}$, rather than $G\alpha_{i/o}$ would certainly be a valuable pharmacological tool to unravel the relative importance of FFA2 signaling pathway/s and their biological role in pancreatic beta cells and potentially in type 2 diabetes.

Limits and extensions to FFA2 and FF3 knock-out studies

As highlighted earlier, a useful technique for discovering the function of GPCRs is to create transgenic mouse knock-out models, and characterize the resulting phenotype(s). In the case of FFA2 and FFA3 however, the results of knocking out either receptor have proven to be conflicting. For example, a disparity is seen in adiposity between the different knock-out models. The FFA2 knock-out mouse produced by Kimura *et al.* is heavier than the wild type, and has more adipose tissue (Kimura *et al.*, 2013), but another model shows no difference in weight gain between wild type and knock-out (Tang *et al.*, 2015), while yet another actually shows the knock-out is protective against weight gain on a high fat diet (Priyadarshini *et al.*, 2015). Likewise FFA3 knock-out models have both increased adiposity (Bellahcene *et al.*, 2013), and the same amount of adipose tissue as wild type (Samuel *et al.*, 2008). Model-dependent differences have also been observed in glucose tolerance and insulin sensitivity in both FFA2 (Bjursell *et al.*, 2011; Tolhurst *et al.*, 2012; Priyadarshini *et al.*, 2015; Tang *et al.*, 2015) and FFA3 knock-out lines (Kimura *et al.*, 2011; Tolhurst *et al.*, 2012; Tang *et al.*, 2015).

These discrepancies may be for one of two reasons. Firstly, as the endogenous ligands for FFA2 for FFA3 overlap between the two receptors, knock-out of one may simply result in the compensation by the other. Secondly, *FFAR2* and *FFAR3* in mouse are located adjacent to each other on chromosome 7. Attempts to alter the transcript for one gene may affect the transcription of the other. One group has indeed reported that FFA2 was down-regulated in their FFA3 knock-out model (Zaibi *et al.*, 2010), while others have not checked for this issue.

Chemogenetic approaches to determining the physiological function and drug responses of FFA2 and FFA3

Whereas gene knock-out studies provide an approach for understanding the physiological role of FFA2 and FFA3 and provide important indications of the physiological impact and clinical potential of targeting these receptors, there are more sophisticated genetic approaches that can be adopted that can provide a direct measure of the impact of pharmacologically selective ligands. Work centered largely on the muscarinic receptor family has provided the framework for the development of a chemogenetic approach where mutations introduced into the orthosteric binding site of receptors result in a loss of activity to the natural ligand but, instead, allows the receptor to be activated by a synthetic chemical ligand that is otherwise inert (Armbruster *et al.*, 2007; Dong *et al.*, 2010; Alvarez-Curto *et al.*, 2011; Urban and Roth, 2015). Such receptor mutants have been termed Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) and have been used extensively to define G protein dependent *in vivo* responses (Urban and Roth, 2015).

Using the distinct endogenous ligand selectivity of bovine and human FFA2, two mutations introduced into the orthosteric binding site of human FFA2 reduced the response of the receptor to endogenous SCFAs by >100 fold. This receptor mutant was instead activated by sorbic acid, a naturally produced but not endogenously generated ligand, that activates bovine FFA2 but not human FFA2, as well as a series of small synthetic compounds (Hudson *et al.*, 2012a) (**Figure 3**). Hence these studies generated the first genuine FFA2-DREADD receptor which possessed the following properties (i) the FFA2-DREADD was no longer activated by endogenous SCFAs, (ii) instead this

receptor mutant was activated by a synthetic chemical ligand (e.g. in this case sorbic acid) and (iii) the wild type receptor (i.e. human FFA2) was not activated by the synthetic ligand (Hudson *et al.*, 2012a) (**Figure 3**).

This FFA2-DREADD opens up the possibility of employing a chemogenetic approach akin to that successfully employed by the muscarinic-DREADDs. Hence, by using gene targeting techniques that replace the mouse FFA2 gene with the coding sequence for the FFA2-DREADD then the mutant receptor will be expressed at physiologically relevant levels and in the same cell types as the wild type FFA2. By administration of sorbic acid to these FFA2-DREADD mutant mice researchers will not only be able to define the physiological role of FFA2 but also this approach will provide the first insights into the potential therapeutic response that can be expected of a drug that selectively targets FFA2 (**Figure 3**). Moreover, the FFA2-DREADD retains high affinity for the human specific antagonist ligands CATPB and GLPG0974. As such, on target, FFA2-DREADD mediated effects of sorbic acid will block such effects but not potential off target effects (**Figure 3**). It will be fascinating to see the results of such studies, not least as FFA3 will still be responsive to the endogenously generated SCFAs.

Conclusions

SCFA receptors are relatively newly discovered GPCRs. Emerging evidence suggests that these receptors are implicated in a variety of physiological functions and their pharmacological modulation could represent invaluable therapeutic targets. However, translational pharmacology has been limited by a paucity of selective ligands and by receptor species ortholog differences. Moreover, animal genetic knock-out

approaches have resulted in challenging data interpretation, due perhaps to compensatory effects.

Alternative and more refined strategies, such as the DREADD chemogenetic approach may hold great potential to unravel the impact of pharmacologically selective ligands at FFA2, and also define the physiological importance of FFA2 vs FFA3.

Authorship contributions

Wrote the manuscript DB, CEM, ABT, GM

References

Akiba Y, Inoue T, Kaji I, Higashiyama M, Narimatsu K, Iwamoto K, Watanabe M, Guth PH, Engel E, Kuwahara A, and Kaunitz JD (2015) Short-chain fatty acid sensing in rat duodenum. *J Physiol (Lond)* **593**:585–599.

Al-Lahham SH, Peppelenbosch MP, Roelofsen H, Vonk RJ, and Venema K (2010) Biological effects of propionic acid in humans; metabolism, potential applications and underlying mechanisms. *Biochim Biophys Acta* **1801**:1175–1183.

Alvarez-Curto E, Prihandoko R, Tautermann CS, Zwier JM, Pediani JD, Lohse MJ, Hoffmann C, Tobin AB, and Milligan G (2011) Developing chemical genetic approaches to explore G protein-coupled receptor function: validation of the use of a receptor activated solely by synthetic ligand (RASSL). *Mol Pharmacol* **80**:1033–1046.

Armbruster BN, Li X, Pausch MH, Herlitze S, and Roth BL (2007) Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. *Proc Natl Acad Sci U S A* **104**:5163–5168.

Bellahcene M, O'Dowd JF, Wargent ET, Zaibi MS, Hislop DC, Ngala RA, Smith DM, Cawthorne MA, Stocker CJ, and Arch JR (2013) Male mice that lack the G-protein-coupled receptor GPR41 have low energy expenditure and increased body fat content. *Br J Nutr* **109**:1755–1764.

Bjursell M, Admyre T, Göransson M, Marley AE, Smith DM, Oscarsson J, and

Bohlooly-Y M (2011) Improved glucose control and reduced body fat mass in

free fatty acid receptor 2-deficient mice fed a high-fat diet. *Am J Physiol*

Endocrinol Metab **300**:E211–E220.

Bocker U, Nebe T, Herweck F, Holt L, Panja A, Jobin C, Rossol S, B. Sartor R, and

Singer M (2003) Butyrate modulates intestinal epithelial cell-mediated neutrophil

migration. *Clin Exp Immunol* **131**:53–60.

Brantis C, Ooms F, and Bernard J (2011) Novel amino acid derivatives and their use as

gpr43 receptor modulators. *PCT Int. Appl.* WO2011092284.

Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, Muir AI,

Wigglesworth MJ, Kinghorn I, Fraser NJ, Pike NB, Strum JC, Steplewski KM,

Murdock PR, Holder JC, Marshall FH, Szekeres PG, Wilson S, Ignar DM, Foord

SM, Wise A, and Dowell SJ (2003) The Orphan G protein-coupled receptors

GPR41 and GPR43 are activated by propionate and other short chain carboxylic

acids. *J Biol Chem* **278**:11312–11319.

Brown AJ, Tsoulou C, Ward E, Gower E, Bhudia N, Chowdhury F, Dean TW, Faucher

N, Gangar A, and Dowell SJ (2015) Pharmacological properties of acid N-

thiazolylamide FFA2 agonists. *Pharmacol Res Perspect* **3**:e00141.

Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, and Calignano A (2011) Potential

beneficial effects of butyrate in intestinal and extraintestinal diseases. *World J*

Gastroenterol **17**:1519–1528.

Cavaglieri C, Nishiyama A, Fernandes L, Curi R, Miles E, and Calder P (2003)
Differential effects of short-chain fatty acids on proliferation and production of
pro- and anti-inflammatory cytokines by cultured lymphocytes. *Life Sci* **73**:1683–
1690.

Chen L, and Jan C (2001) Mechanisms and modulation of formyl-methionyl-leucyl-
phenylalanine (fMLP)-induced Ca2+ mobilization in human neutrophils. *Int
Immunopharmacol* **1**:1341–1349.

Crouse JR, Gerson CD, DeCarli LM, and Lieber CS (1968) Role of acetate in the
reduction of plasma free fatty acids produced by ethanol in man. *J Lipid Res*
9:509–512.

Dass NB, John AK, Bassil AK, Crumbley CW, Shehee WR, Maurio FP, Moore GB,
Taylor CM, and Sanger GJ (2007) The relationship between the effects of short-
chain fatty acids on intestinal motility in vitro and GPR43 receptor activation.
Neurogastroenterol Motil **19**:66–74.

De Vadder F, Kovatcheva-Datchary P, Goncalves D, Vinera J, Zitoun C, Duchampt A,
Bäckhed F, and Mithieux G (2014) Microbiota-generated metabolites promote
metabolic benefits via gut-brain neural circuits. *Cell* **156**:84–96.

Den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, and Bakker BM
(2013) The role of short-chain fatty acids in the interplay between diet, gut
microbiota, and host energy metabolism. *J Lipid Res* **54**:2325–2340.

Dewulf EM, Ge Q, Bindels LB, Sohet FM, Cani PD, Brichard SM, and Delzenne NM

(2013) Evaluation of the relationship between GPR43 and adiposity in human.

Nutr Metab (Lond) **10**:11.

Dong S, Rogan SC, and Roth BL (2010) Directed molecular evolution of DREADDs: a

generic approach to creating next-generation RASSLs. *Nat Protocol* **5**:561–573.

Dranse HJ, Kelly ME, and Hudson BD (2013) Drugs or diet?--Developing novel

therapeutic strategies targeting the free fatty acid family of GPCRs. *Br J

Pharmacol* **170**:696–711.

Engelstoft M, M. Park W, Sakata I, V. Kristensen L, S. Husted A, Osborne-Lawrence S,

K. Piper P, K. Walker A, H. Pedersen M, K. Nohr M, Pan J, J. Sinz C, E.

Carrington P, E. Akiyama T, M. Jones R, Tang C, Ahmed K, Offermanns S, L.

Egerod K, M. Zigman J, and W. Schwartz T (2013) Seven transmembrane G

protein-coupled receptor repertoire of gastric ghrelin cells. *Mol Metabol* **2**:376–

392.

Ge H, Li X, Weiszmann J, Wang P, Baribault H, Chen JL, Tian H, and Li Y (2008)

Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition of

lipolysis and suppression of plasma free fatty acids. *Endocrinol* **149**:4519–4526.

Gee JM, Lee-Finglas W, Wortley GW, and Johnson IT (1996) Fermentable carbohydrates

elevate plasma enteroglucagon but high viscosity is also necessary to stimulate

small bowel mucosal cell proliferation in rats. *J Nutr* **126**:373–379.

Hattori H, Subramanian KK, Sakai J, Jia Y, Li Y, Porter TF, Loison F, Sarraj B, Kasorn A, Jo H, Blanchard C, Zirkle D, McDonald D, Pai SY, Serhan CN, and Luo HR (2010) Small-molecule screen identifies reactive oxygen species as key regulators of neutrophil chemotaxis. *Proc Natl Acad Sci U S A* **107**:3546–3551.

He W, Miao FJ, Lin DC, Schwandner RT, Wang Z, Gao J, Chen JL, Tian H, and Ling L (2004) Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. *Nature* **429**:188–193.

Hong YH, Nishimura Y, Hishikawa D, Tsuzuki H, Miyahara H, Gotoh C, Choi KC, Feng DD, Chen C, Lee HG, Katoh K, Roh SG, and Sasaki S (2005) Acetate and propionate short chain fatty acids stimulate adipogenesis via GPCR43. *Endocrinol* **146**:5092–5099.

Hopkins AL, Keserü GM, Leeson PD, Rees DC, and Reynolds CH (2014) The role of ligand efficiency metrics in drug discovery. *Nat Rev Drug Discov* **13**:105–121.

Hoveyda H, E. Brantis C, Dutheuil G, Zoute L, Schils D, and Bernard J (2010) Compounds, pharmaceutical composition and methods for use in treating metabolic disorders. *PCT Int. Appl.* WO2011076732.

Hudson BD, Christiansen E, Murdoch H, Jenkins L, Hansen AH, Madsen O, Ulven T, and Milligan G (2014) Complex pharmacology of novel allosteric free fatty acid 3 receptor ligands. *Mol Pharmacol* **86**:200–210.

Hudson BD, Due-Hansen ME, Christiansen E, Hansen AM, Mackenzie AE, Murdoch H, Pandey SK, Ward RJ, Marquez R, Tikhonova IG, Ulven T, and Milligan G (2013b) Defining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptor. *J Biol Chem* **288**:17296–17312.

Hudson BD, Christiansen E, Tikhonova IG, Grundmann M, Kostenis E, Adams DR, Ulven T and Milligan G (2012a) Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs. *FASEB J* **26**:4951-4965.

Hudson BD, Tikhonova IG, Pandey SK, Ulven T, and Milligan G (2012b) Extracellular ionic locks determine variation in constitutive activity and ligand potency between species orthologs of the free fatty acid receptors FFA2 and FFA3. *J Biol Chem* **287**:41195–41209.

Hudson BD, Ulven T, and Milligan G (2013a) The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs. *Curr Top Med Chem* **13**:14–25.

Inoue D, Kimura I, Wakabayashi M, Tsumoto H, Ozawa K, Hara T, Takei Y, Hirasawa A, Ishihama Y, and Tsujimoto G (2012) Short-chain fatty acid receptor GPR41-mediated activation of sympathetic neurons involves synapsin 2b phosphorylation. *FEBS Lett* **586**:1547–1554.

Kataoka K, Ogasa S, Kuwahara T, Bando Y, Hagiwara M, Arimochi H, Nakanishi S, Iwasaki T, and Ohnishi Y (2008) Inhibitory effects of fermented brown rice on

induction of acute colitis by dextran sulfate sodium in rats. *Dig Dis Sci* **53**:1601–1608.

Kenakin T (2013) New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2. *Br J Pharmacol* **168**:554–575.

Kenakin T (2015) The effective application of biased signaling to new drug discovery. *Mol Pharmacol* **88**:1055-1061

Kenakin T, and Christopoulos A (2013) Signalling bias in new drug discovery: detection, quantification and therapeutic impact. *Nat Rev Drug Discov* **168**:554-575.

Kenakin T, and J. Miller L (2010) Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. *Pharmacol Rev* **62**:265–304.

Kim MH, Kang SG, Park JH, Yanagisawa M, and Kim CH (2013) Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. *Gastroenterol* **145**:396–406.e1.

Kimura I, Inoue D, Maeda T, Hara T, Ichimura A, Miyauchi S, Kobayashi M, Hirasawa A, and Tsujimoto G (2011) Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). *Proc Natl Acad Sci U S A* **108**:8030–8035.

Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda T, Terasawa K, Kashihara D, Hirano K, Tani T, Takahashi T, Miyauchi S, Shioi G, Inoue H, and Tsujimoto

G (2013) The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. *Nat Commun* **4**:1829.

Lane J, M. R. Sexton P, and Christopoulos A (2013) Bridging the gap: bitopic ligands of G-protein-coupled receptors. *Trends Pharmacol Sci* **34**:59–66.

Layden BT, Durai V, Newman MV, Marinelarena AM, Ahn CW, Feng G, Lin S, Zhang X, Kaufman DB, Jafari N, Sørensen GL, and Lowe WL (2010) Regulation of pancreatic islet gene expression in mouse islets by pregnancy. *J Endocrinol* **207**:265–279.

Le Poul E, Loison C, Struyf S, Springael JY, Lannoy V, Decobecq ME, Brezillon S, Dupriez V, Vassart G, Van Damme J, Parmentier M, and Detheux M (2003) Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. *J Biol Chem* **278**:25481–25489.

Lee S, J. U. In H, S. Kwon M, O. Park B, Jo M, O. Kim M, Cho S, Lee S, J. Lee H, S. Kwak Y, and Kim S (2013) beta-Arrestin 2 mediates G protein-coupled receptor 43 signals to nuclear factor-kappaB. *Biol Pharmaceut Bull* **36**:1754–1759.

Lee T, Schwandner R, Swaminath G, Weiszmann J, Cardozo M, Greenberg J, Jaeckel P, Ge H, Wang Y, Jiao X, Liu J, Kayser F, Tian H, and Li Y (2008) Identification and functional characterization of allosteric agonists for the G protein-coupled receptor FFA2. *Mol Pharmacol* **74**:1599–1609.

Lemor A, Mielenz M, Altmann M, von Borell E, and Sauerwein H (2010) mRNA abundance of adiponectin and its receptors, leptin and visfatin and of G-protein coupled receptor 41 in five different fat depots from sheep. *J Anim Physiol Anim Nutr (Berl)* **94**:e96–101.

Leonard JN, Chu ZL, Bruce MA, and Boatman PD (2006) Gpr41 and modulators thereof for the treatment of insulin-related disorders. Patent number US 20080312277 A1.

Liaw C, W. and T. Connolly D (2009) Sequence polymorphisms provide a common consensus sequence for GPR41 and GPR42. *DNA Cell Biol* **28**:555–560.

Lin HV, Frassetto A, Kowalik EJ, Nawrocki AR, Lu MM, Kosinski JR, Hubert JA, Szeto D, Yao X, Forrest G, and Marsh DJ (2012) Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. *PLoS ONE* **7**:e35240.

Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, Schilter HC, Rolph MS, Mackay F, Artis D, Xavier RJ, Teixeira MM, and Mackay CR (2009) Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. *Nature* **461**:1282–1286.

May LT, Leach K, Sexton PM, and Christopoulos A (2007) Allosteric modulation of G protein-coupled receptors. *Annu Rev Pharmacol Toxicol* **47**:1–51.

McOrist AL, Abell GC, Cooke C, and Nyland K (2008) Bacterial population dynamics and faecal short-chain fatty acid (SCFA) concentrations in healthy humans. *Br J Nutr* **100**:138–146.

Mielenz M, Seybold C, and Sauerwein H (2008) Effects of short-term infusion with propionate on the mRNA expression of a putative G-protein coupled receptor 41 (GPR41) in adipose tissue of goats. *Livest Sci* **116**:328–331.

Milligan G, Stoddart LA, and Smith NJ (2009) Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3. *Br J Pharmacol* **158**:146–153.

Milligan G, Ulven T, Murdoch H, and Hudson BD (2014) G-protein-coupled receptors for free fatty acids: nutritional and therapeutic targets. *Br J Nutr* **111 Suppl 1**:S3–S7.

Nakao S, Fujii A, and Niederman R (1992) Alteration of cytoplasmic Ca2+ in resting and stimulated human neutrophils by short-chain carboxylic acids at neutral pH. *Infect Immun* **60**:5307–5311.

Nilsson AC, Östman EM, Knudsen KE, Holst JJ, and Björck IM (2010) A cereal-based evening meal rich in indigestible carbohydrates increases plasma butyrate the next morning. *J Nutr* **140**:1932–1936.

Nilsson NE, Kotarsky K, Owman C, and Olde B (2003) Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. *Biochem Biophys Res Commun* **303**:1047–1052.

Nøhr MK, Egerod KL, Christiansen SH, Gille A, Offermanns S, Schwartz TW, and Møller M (2015) Expression of the short chain fatty acid receptor GPR41/FFAR3 in autonomic and somatic sensory ganglia. *Neuroscience* **290**:126–137.

Nøhr MK, Pedersen MH, Gille A, Egerod KL, Engelstoft MS, Husted AS, Sichlau RM, Grunddal KV, Poulsen SS, Han S, Jones RM, Offermanns S, and Schwartz TW (2013) GPR41/FFAR3 and GPR43/FFAR2 as cosensors for short-chain fatty acids in enteroendocrine cells vs FFAR3 in enteric neurons and FFAR2 in enteric leukocytes. *Endocrinol* **154**:3552–3564.

Nordenfelt P, and Tapper H (2011) Phagosome dynamics during phagocytosis by neutrophils. *J Leukoc Biol* **90**:271–284.

Ohira H, Fujioka Y, Katagiri C, Mamoto R, Aoyama-Ishikawa M, Amako K, Izumi Y, Nishiumi S, Yoshida M, Usami M, and Ikeda M (2013) Butyrate attenuates inflammation and lipolysis generated by the interaction of adipocytes and macrophages. *J Atheroscler Thromb* **20**:425–442.

Patel DG, and Singh SP (1979) Effect of ethanol and its metabolites on glucose mediated insulin release from isolated islets of rats. *Metab Clin Exp* **28**:85–89.

Pizzonero M, Dupont S, Babel M, Beaumont S, Bienvenu N, Blanqué R, Cherel L, Christophe T, Crescenzi B, De Lemos E, Delerive P, Deprez P, De Vos S, Djata F, Fletcher S, Kopiejewski S, L'Ebraly C, Lefrançois JM, Lavazais S, Manioc M, Nelles L, Oste L, Polancec D, Quénéhen V, Soulas F, Triballeau N, van der Aar EM, Vandeghinste N, Wakselman E, Brys R, and Saniere L (2014) Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinic. *J Med Chem* **57**:10044–10057.

Pratt VC, Tappenden KA, McBurney MI, and Field CJ (1996) Short-chain fatty acid-supplemented total parenteral nutrition improves nonspecific immunity after intestinal resection in rats. *JPEN J Parenter Enteral Nutr* **20**:264–271.

Priyadarshini M, and Layden BT (2015) FFAR3 modulates insulin secretion and global gene expression in mouse islets. *Islets* **7**:e1045182

Priyadarshini M, Villa SR, Fuller M, Wicksteed B, Mackay CR, Alquier T, Poitout V, Mancebo H, Mirmira RG, Gilchrist A, and Layden BT (2015) An Acetate-Specific GPCR, FFAR2, Regulates Insulin Secretion. *Mol Endocrinol* **29**:1055–1066.

Psichas A, Sleeth ML, Murphy KG, Brooks L, Bewick GA, Hanyaloglu AC, Ghatei MA, Bloom SR, and Frost G (2015) The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents. *Int J Obes (Lond)* **39**:424–429.

Puhl HL, Won YJ, Lu VB, and Ikeda SR (2015) Human GPR42 is a transcribed multisite variant that exhibits copy number polymorphism and is functional when heterologously expressed. *Sci Rep* **5**:12880.

Regard JB, Kataoka H, Cano DA, Camerer E, Yin L, Zheng YW, Scanlan TS, Hebrok M, and Coughlin SR (2007) Probing cell type-specific functions of Gi in vivo identifies GPCR regulators of insulin secretion. *J Clin Invest* **117**:4034–4043.

Reimer RA, and McBurney MI (1996) Dietary fiber modulates intestinal proglucagon messenger ribonucleic acid and postprandial secretion of glucagon-like peptide-1 and insulin in rats. *Endocrinology* **137**:3948–3956.

Robertson MD, Bickerton AS, Dennis AL, Vidal H, and Frayn KN (2005) Insulin-sensitizing effects of dietary resistant starch and effects on skeletal muscle and adipose tissue metabolism. *Am J Clin Nutr* **82**:559–567.

Sabirsh A, Bywater RP, Bristulf J, Owman C, and Haeggström JZ (2006) Residues from transmembrane helices 3 and 5 participate in leukotriene B4 binding to BLT1. *Biochemistry* **45**:5733–5744.

Säemann MD, Böhmig GA, Osterreicher CH, Burtscher H, Parolini O, Diakos C, Stöckl J, Hörl WH, and Zlabinger GJ (2000) Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production. *FASEB J* **14**:2380–2382.

Samuel BS, Shaito A, Motoike T, Rey FE, Backhed F, Manchester JK, Hammer RE, Williams SC, Crowley J, Yanagisawa M, and Gordon JI (2008) Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. *Proc Natl Acad Sci U S A* **105**:16767–16772.

Sanière LRM, Pizzonero MR, Triballeau N, Vandeghinste NER, DE Vossij, Brys RCX and Pourbaix-L'Ebraly CD (2012) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases. PCT Int. Appl. WO2011098033 A1.

Sawzdargo M, George SR, Nguyen T, Xu S, Kolakowski LF, and O'Dowd BF (1997) A cluster of four novel human G protein-coupled receptor genes occurring in close proximity to CD22 gene on chromosome 19q13.1. *Biochem Biophys Res Commun* **239**:543–547.

Schmidt J, Smith NJ, Christiansen E, Tikhonova IG, Grundmann M, Hudson BD, Ward RJ, Drewke C, Milligan G, Kostenis E, and Ulven T (2011) Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. *J Biol Chem* **286**:10628–10640.

Sergeev E, Hansen H, Pandey SK, MacKenzie AE, Hudson BD, Ulven T, and Milligan G. (2016) Non-Equivalence of key positively charged residues of the Free Fatty Acid 2 Receptor in the recognition and function of agonist versus antagonist ligands. *J Biol Chem*, in press

Sethi JK, and Vidal-Puig AJ (2007) Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. *J Lipid Res* **48**:1253–1262.

Shah JH, Wongsurawat N, and Aran PP (1977) Effect of ethanol on stimulus-induced insulin secretion and glucose tolerance. A study of mechanisms. *Diabetes* **26**:271–277.

Sina C, Gavrilova O, Förster M, Till A, Derer S, Hildebrand F, Raabe B, Chalaris A, Scheller J, Rehmann A, Franke A, Ott S, Häsler R, Nikolaus S, Fölsch UR, Rose-John S, Jiang HP, Li J, Schreiber S, and Rosenstiel P (2009) G protein-coupled receptor 43 is essential for neutrophil recruitment during intestinal inflammation. *J Immunol* **183**:7514–7522.

Smith C (2003) Drug target validation: Hitting the target. *Nature* **422**:341, 343, 345 passim.

Smith NJ, Ward RJ, Stoddart LA, Hudson BD, Kostenis E, Ulven T, Morris JC, Tränkle C, Tikhonova IG, Adams DR, and Milligan G (2011) Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric modulator. *Mol Pharmacol* **80**:163–173.

Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, Glickman JN, and Garrett WS (2013) The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. *Science* **341**:569–573.

Soliman M, Kimura K, Ahmed M, Yamaji D, Matsushita Y, Okamatsu-Ogura Y, Makondo K, and Saito M (2007) Inverse regulation of leptin mRNA expression by short- and long-chain fatty acids in cultured bovine adipocytes. *Domest Anim Endocrinol* **33**:400–409.

Stitham J, Stojanovic A, Merenick BL, O'Hara KA, and Hwa J (2003) The unique ligand-binding pocket for the human prostacyclin receptor. Site-directed mutagenesis and molecular modeling. *J Biol Chem* **278**:4250–4257.

Stoddart L, J. Smith N, and Milligan G (2008a) International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions. *Pharmacol Rev* **60**:405–417.

Stoddart LA, Smith NJ, Jenkins L, Brown AJ, and Milligan G (2008b) Conserved polar residues in transmembrane domains V, VI, and VII of free fatty acid receptor 2 and free fatty acid receptor 3 are required for the binding and function of short chain fatty acids. *J Biol Chem* **283**:32913–32924.

Tang C, Ahmed K, Gille A, Lu S, Gröne HJ, Tunaru S, and Offermanns S (2015) Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes. *Nat Med* **21**:173–177.

Tang Y, Chen Y, Jiang H, Robbins GT, and Nie D (2011) G-protein-coupled receptor for short-chain fatty acids suppresses colon cancer. *Int J Cancer* **128**:847–856.

Tappenden KA, and McBurney MI (1998) Systemic short-chain fatty acids rapidly alter

gastrointestinal structure, function, and expression of early response genes. *Dig

Dis Sci* **43**:1526–1536.

Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, Cameron J,

Grosse J, Reimann F, and Gribble FM (2012) Short-chain fatty acids stimulate

glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2.

Diabetes **61**:364–371.

Topping DL, and Clifton PM (2001) Short-chain fatty acids and human colonic function:

roles of resistant starch and nonstarch polysaccharides. *Physiol Rev* **81**:1031–

1064.

Tunaru S, Lättig J, Kero J, Krause G, and Offermanns S (2005) Characterization of

determinants of ligand binding to the nicotinic acid receptor GPR109A

(HM74A/PUMA-G). *Mol Pharmacol* **68**:1271–1280.

Ulven T (2012) Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as

new potential therapeutic targets. *Front Endocrinol (Lausanne)* **3**:111.

Urban DJ, and Roth BL (2015) DREADDs (designer receptors exclusively activated by

designer drugs): chemogenetic tools with therapeutic utility. *Annu Rev Pharmacol

Toxicol* **55**:399–417.

Vieira AT, Macia L, Galvão I, Martins FS, Canesso MC, Amaral FA, Garcia CC,

Maslowski KM, De Leon E, Shim D, Nicoli JR, Harper JL, Teixeira MM, and

Mackay CR (2015) A Role for Gut Microbiota and the Metabolite-Sensing Receptor GPR43 in a Murine Model of Gout. *Arthritis Rheumatol* **67**:1646–1656.

Vinolo MA, Ferguson GJ, Kulkarni S, Damoulakis G, Anderson K, Bohlooly-Y M, Stephens L, Hawkins PT, and Curi R (2011) SCFAs induce mouse neutrophil chemotaxis through the GPR43 receptor. *PLoS ONE* **6**:e21205.

Vinolo MA, Hatanaka E, Lambertucci RH, Newsholme P, and Curi R (2009) Effects of short chain fatty acids on effector mechanisms of neutrophils. *Cell Biochem Funct* **27**:48–55.

Wang A, Akers RM, and Jiang H (2012) Short communication: Presence of G protein-coupled receptor 43 in rumen epithelium but not in the islets of Langerhans in cattle. *J Dairy Sci* **95**:1371–1375.

Wang Y, Jiao X, Kayser F, Liu J, Wang Z, Wanska M, Greenberg J, Weiszmann J, Ge H, Tian H, Wong S, Schwandner R, Lee T, and Li Y (2010) The first synthetic agonists of FFA2: Discovery and SAR of phenylacetamides as allosteric modulators. *Bioorg Med Chem Lett* **20**:493–498.

Winzell MS, and Ahrén B (2007) G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes. *Pharmacol Ther* **116**:437–448.

Won YJ, Lu VB, Puhl HL, and Ikeda SR (2013) β-Hydroxybutyrate modulates N-type calcium channels in rat sympathetic neurons by acting as an agonist for the G-protein-coupled receptor FFA3. *J Neurosci* **33**:19314–19325.

Wong JM, de Souza R, Kendall CW, Emam A, and Jenkins DJ (2006) Colonic health: fermentation and short chain fatty acids. *J Clin Gastroenterol* **40**:235–243.

Wootten D, Christopoulos A, and Sexton PM (2013) Emerging paradigms in GPCR allostery: implications for drug discovery. *Nat Rev Drug Discov* **12**:630–644.

Xavier RJ, and Podolsky DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. *Nature* **448**:427–434.

Xiong Y, Miyamoto N, Shibata K, Valasek MA, Motoike T, Kedzierski RM, and Yanagisawa M (2004) Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41. *Proc Natl Acad Sci U S A* **101**:1045–1050.

Yajima H, Komatsu M, Schermerhorn T, Aizawa T, Kaneko T, Nagai M, Sharp GW, and Hashizume K (1999) cAMP enhances insulin secretion by an action on the ATP-sensitive K+ channel-independent pathway of glucose signaling in rat pancreatic islets. *Diabetes* **48**:1006–1012.

Zaibi MS, Stocker CJ, O'Dowd J, Davies A, Bellahcene M, Cawthorne MA, Brown AJ, Smith DM, and Arch JR (2010) Roles of GPR41 and GPR43 in leptin secretory responses of murine adipocytes to short chain fatty acids. *FEBS Lett* **584**:2381–2386.

Zweemer AJ, Toraskar J, Heitman LH, and IJzerman AP (2014) Bias in chemokine receptor signalling. *Trends Immunol* **35**:243–252.

Footnotes

DB and CEM contributed equally to this work.

Legends for Figures

Figure 1

Selectivity of ligands at human and murine FFA2 and FFA3. The main endogenous SCFAs (C2, C3 and C4) activate FFA2 and FFA3 with varying potency (denoted by the thickness of the arrow) and the rank order of activity is not maintained between human and mouse species orthologs (Hudson *et al.*, 2012b). Synthetic allosteric agonists at FFA2 are represented by phenylacetamides, where 4-CMTB is the most potent ligand (Lee *et al.*, 2008; Wang *et al.*, 2010; Smith *et al.*, 2011) and it maintains its activity across human and mouse FFA2 (Hudson *et al.*, 2012b). Allosteric modulators at FFA3 are represented by a class of synthetic ligands that comprises allosteric agonists, such as AR420626, and allosteric antagonists, such as 'compound 6' (Hudson *et al.*, 2014). Both AR420626 and 'compound 6' maintain their activity at the murine species ortholog (Nøhr *et al.*, 2013; Engelstoft *et al.*, 2013; Hudson *et al.*, 2014). Synthetic orthosteric agonists at FFA2 are represented by 'Compound 1' (Hudson *et al.*, 2013b) and SCAs with sp and sp^2 hybridized α carbon (Schimdt *et al.*, 2011). Alternative, SCAs with substituted sp^3 hybridized α carbon have a degree of selectivity for FFA3 (Schimdt *et al.*, 2011). The degree of selectivity of 'compound 1' and SCAs is relatively well maintained between human and mouse species orthologs (Hudson *et al.*, 2012b and 2013b). Synthetic orthosteric antagonists at FFA2 are represented by GLPG0974 and CATPB, however these compounds show affinity only for the human species ortholog (Hudson *et al.*, 2012b; Sergeev *et al.*, 2015).

Figure 2

Key actions of SCFAs at sites which express FFA2 and/or FFA3. The physiological roles

of FFA2 and FFA3 are complex, and yet to be completely elucidated. Details that remain

contentious are marked with a '?'. In PMNs/PBMCs FFA2 causes chemotaxis down a

SCFA gradient, and elicits changes in ROS signaling and cytokine release (Säemann *et*

al., 2000; Cavaglieri *et al.,* 2003; Sina et *al.,* 2009; Vinolo *et al.,* 2009, 2011). In

enteroendocine cells, FFA2 and FFA3 cause secretion of a variety of gut hormones (Lin

et al., 2012; Tolhurst *et al.,* 2012; Akiba *et al.,* 2015; Psichas *et al.,* 2015). FFA2

promotes adipogenesis, decreases lipolysis, and possibly increases leptin secretion from

adipocytes (Xiong *et al.,* 2004; Hong *et al.,* 2005; Ge *et al.,* 2008; Zaibi *et al.,* 2010).

FFA3 in neurons increases sympathetic innervation and increases plasticity in the enteric

nervous system (Soret *et al.,* 2010; Kimura *et al.,* 2011). In the pancreas acetate may

increase and propionate decrease insulin secretion (Priyadarshini and Layden, 2015;

Priyadarshini *et al.,* 2015).

Figure 3

Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) strategy for

FFA2. In wild type animals, FFA2 and FFA3 are both activated by SCFAs, i.e.

propionate (C3). In tissues co-expressing both SCFA receptors, the physiological

response of C3 results from the activation of both FFA2 and FFA3. In mice engineered

with the humanized FFA2-DREADD, the mutated FFA2 is solely activated by the

administration of the non-endogenous ligand, sorbic acid, and inert to the endogenous

ligand, C3. Hence, the physiological responses of C3 results only from FFA3 activation,

while the responses of sorbic acid is uniquely mediated by FFA2-DREADD activation.

Moreover, the FFA2-DREADD retains high affinity for the human specific antagonist

ligands CATPB and GLPG0974. As such, on-target FFA2-DREADD-mediated responses

of sorbic acid will be blocked by these antagonists but not potential off-target effects.

Figure 1

orthosteric antagonist

CATPB

GLPG0974

orthosteric agonist

'Compound 1'

SCAs
(sp and sp2
hybridized α carbon)

allosteric agonist

4-CMTB

endogenous SCFAs

C4

C3

C2

FFA2

FFA3

HUMAN

MOUSE

allosteric antagonist

'Compound 6'

orthosteric agonist

SCAs
(substituted sp3
hybridized α carbon)

allosteric agonist

AR420626

allosteric agonist

4-CMTB

orthosteric agonist

'Compound 1'

SCAs
(sp and sp2
hybridized α carbon)

C2

C3

C4

endogenous SCFAs

allosteric agonist

AR420626

orthosteric agonist

SCAs
(substituted sp3
hybridized α carbon)

allosteric antagonist

'Compound 6'

Figure 2

β-cells

FFA2, FFA3
↑insulin (C2) (?)
↓insulin (C3) (?)

PMNs/PBMCs

FFA2
↑chemotaxis
anti-inflammatory cytokines
↑ROS (C2)
↓ROS (C4)

H₃C—COO⁻
Acetate 'C2'

H₃C—COO⁻
Propionate 'C3'

H₃C—COO⁻
Butyrate 'C4'

Enteroendocrine Cells

FFA2, FFA3
↑GLP-1, PYY
↑5-HT

Neurons

FFA3
↑sympathetic innervation
enteric nervous system plasticity

Adipocytes

FFA2
↑adipogenesis (C2, C3)
↑leptin (?)
↓lipolysis (C2, C3, C4)

Figure 3

Sorbic Acid

C3

FFA2
orthosteric antagonists
(GLPG0974/ CATPB)

FFA2

FFA3

FFA2
-DREADD

FFA3

Physiological effects of
FFA2 and FFA3 activation

Physiological effects of
FFA2-DREADD activation/inhibition
or FFA3 activation